TaqIA is a polymorphism associated with addictions and dopamine-related traits. It is located in the ankyrin repeat and kinase domain containing 1 gene (ANKK1) nearby the gene for the dopamine D2 receptor (D2R). Since ANKK1 function is unknown, TaqIA-associated traits have been explained only by differences in D2R. Here we report ANKK1 studies in mouse and human brain using quantitative real-time PCR, Western blot, immunohistochemistry, and flow cytometry. ANKK1 mRNA and protein isoforms vary along neurodevelopment in the human and mouse brain. In mouse adult brain ANKK1 is located in astrocytes, nuclei of postmitotic neurons and neural precursors from neurogenic niches. In both embryos and adults, nuclei of neural precursors show significant variation of ANKK1 intensity. We demonstrate a correlation between ANKK1 and the cell cycle. Cell synchronization experiments showed a significant increment of ANKK1-kinase in mitotic cells while ANKK1-kinase overexpression affects G1 and M phase that were found to be modulated by ANKK1 alleles and apomorphine treatment. Furthermore, during embryonic neurogenesis ANKK1 was expressed in slow-dividing neuroblasts and rapidly dividing precursors which are mitotic cells. These results suggest a role of ANKK1 during the cell cycle in neural precursors thus providing biological support to brain structure involvement in the TaqIA-associated phenotypes.
Introduction
Addictions are multifactorial disorders that involve neuroadaptative changes in the reward and learning systems of the brain (Koob and Volkow 2010) . To a large extent, genetic factors account for familial aggregation of substance abuse (Kendler et al. 1997; Merikangas et al. 1998) . Indeed, a magnetic resonance imaging study of sibling pairs demonstrated that familial risk for developing addictions is related to inherited differences in brain structure (Ersche et al. 2012) . The most studied genetic variant associated with addictions is the TaqIA single-nucleotide polymorphism (SNP, rs1800497) (Noble 2003; Ponce et al. 2009; Wang et al. 2012) , which is located in the coding region of the ankyrin repeat and kinase domain containing 1 (ANKK1) gene adjacent to the DRD2 gene for the dopamine D2 receptor (D2R) (Neville et al. 2004) . TaqIA has also been linked to the reward deficiency syndrome, a condition in which the decrease in striatal D2R density induces a state of reward hypofunction that triggers the emergence of compulsive and addiction-like drug/food-taking behaviors (Comings and Blum 2000) . ANKK1 variants might nonetheless act in the dopaminergic system (Garrido et al. 2011) .
Although the function of ANKK1 is not known, in silico evidence has become available for at least 3 isoforms: ANKK1 (with RIP kinase and ankyrin repeat domains), ANKK1-kinase (only the RIP kinase domain), and ANKK1-ankyrin (only the ankyrin repeat domain) (Hoenicka et al. 2010) . TaqIA causes the change of a glutamic acid to lysine at residue 713 (E713K) in the ankyrin repeat domain (Neville et al. 2004) and it is in linkage disequilibrium with the change of an alanine to threonine in position 239 (A239T) in the kinase domain (Garrido et al. 2011) . Specifically, A239T could be a marker for variations in the kinase activity of ANKK1 (Garrido et al. 2011) , thus TaqIA is a marker of ANKK1 differences in both the kinase domain and the ankyrin repeat domain (Hoenicka et al. 2010; Garrido et al. 2011) .
ANKK1, also known as receptor interactor protein (RIP) 5, belongs to the RIP serine-threonine kinase family which is involved in survival, death, and differentiation processes (Meylan and Tschopp 2005; Declercq et al. 2009 ). ANKK1 localization in the radial glial cells (RGCs) points to its participation in neurodevelopment (Hoenicka et al. 2010) . ANKK1 maps to chromosome 11q22-q23 in a 521-kb conserved gene cluster among vertebrates (Mota et al. 2012) , along with the neural cell adhesion molecule 1 (NCAM1) and the DRD2 genes both of which are involved in neurogenesis (Hoglinger et al. 2004; Bonfanti 2006) , as well as with the tetratricopeptide repeat domain 12 gene (TTC12), which is a potential scaffold for multiprotein signaling complexes that contains armadillo repeat domains (Castelo-Branco and Arenas 2006) . Extensive genotyping of the NCAM-TTC12-ANKK1-DRD2 cluster shows that substance abuse is associated with variants of the 4 genes (Dick et al. 2007; Yang et al. 2007; Nelson et al. 2013) , thus suggesting a locus-related developmental impact upon vulnerability to addiction. With regard to ANKK1, magnetic resonance imaging studies of the brains of healthy volunteers have shown the influence of TaqIA on the morphology of the midbrain (Cerasa et al. 2009 ) and the anterior cingulate cortex (Montag et al. 2010) . Given that inherited alterations in brain structure could explain the vulnerability to addictive disorders (Ersche et al. 2012 ), here we hypothesize that the association between TaqIA and addiction is due to the significant role of ANKK1 in neurogenesis during development and in drug-induced changes during adulthood.
Materials and Methods

Biological Samples and Cell Lines
Postmortem human brain samples were obtained from the Division of Pathology of the Hospital Universitario Marqués de Valdecilla (HUMV), Santander, Spain, following the protocols of HUMV and approved by the ethics committee of Cantabria.
BALB/cAnNHsd mice at 12 weeks of age (Harlan Interfauna Ibérica) or mice embryos were used as RNA, protein, and tissue source. Experimental procedures were performed following the European Union Council guidelines (2010/63/EU) and Spanish regulations (RD 1201 (RD /2005 and were approved by the ethics committee of Hospital 12 de Octubre, Madrid.
HeLa, SH-SY5Y neuroblastoma and HEK293T cell lines were grown following standard protocols. Adult hippocampal neural progenitor cells (AHNPCs) from P4 C57BL/6 mice were isolated as described by Peltier et al. (2010) .
Quantitative Real-Time RT-PCR
Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. PolyT primers were used for the reverse transcriptase reaction using Superscript III Reverse Transcriptase Kit (Invitrogen). All quantitative real-time RT-PCR reactions were carried out in triplicate on a 7500 Fast Real-Time PCR System (Applied Biosystems, Waltham, MA) using FastStart Universal SYBR Green Master Rox (Roche, Basel, Switzerland) as previously described (Hoenicka et al. 2010) . Primers used to test human and mouse samples are shown in Supplementary methods.
ANKK1 Antibodies
Rabbit polyclonal anti ANKK1 antibodies were generated by our group against a 14-amino acid peptide corresponding to the kinase domain of the predicted ANKK1 open reading frame (ORF) shared by human, mouse and rat (α-STk antibody); and a 13-amino acid peptide specific of N-terminal of the predicted mouse ANKK1 ORF (α-STk2 antibody) (Hoenicka et al. 2010) . α-STk and α-STk2 specificities were assessed (see Supplementary methods). Western blots were performed as previously described (Hoenicka et al. 2010 ).
Immunohistochemistry
ANKK1 localization was determined by incubation with rabbit polyclonal α-STk or α-STk2 (1:250; brain slices for 72 h and cells for 2 h). After, fluorescent secondary antibodies were used and sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 1:15000, Molecular Probes, Eugene, OR, USA). For colabeling experiments, cell-specific primary antibodies were used (see Supplementary methods). Confocal images were acquired using an inverted Zeiss LSM710 Laser Scanning Microscope (Carl Zeiss, Oberkochen, Germany).
Cell Cycle Analyses
For G1/S synchronization, HeLa cells were treated with 2.5 mM thymidine (Sigma-Aldrich, St. Louis, MO, USA) for 16 h and 5 µg/mL aphidicolin (Sigma-Aldrich) for 12 h. After, cells were released in the cycle in standard culture medium containing 0.04 µg/mL nocodazole (Sigma-Aldrich).
Flow cytometry was used for cell cycle analyses of both asynchronous cultured cells lines and E14.5 forebrain dissociated cells. HeLa, SH-SY5Y and HEK293T cells were transfected with Green Fluorescent Protein (GFP)-tagged versions of ANKK1-kinase proteins (Garrido et al. 2011) . The cells were fixed with 0.5% paraformaldehyde (PFA) and the DNA was stained with propidium iodide (20 μg/mL) containing RNase (200 ng/mL) over night at 4°C. For cycle analysis of E14.5 forebrain (telencephalon and diencephalon) cells, tissue from 3 embryos was incubated with 0.1% collagenase type IV (Gibco) in GHEBS medium during 1 h at 37°C and then treated with 0.1 µg/µL DNase (2 min at RT, Sigma) in supplemented L15 medium (Sigma) and mechanically dissociated by passing several times through a pipette tip. The forebrain cells were fixed with 1% PFA in PBS for 20 min at 4°C, treated with 0.25% Triton X-100 (30 min at 4°C, Sigma) and double immunolabeled with α-STk2 (1:250) and anti-beta 3 tubulin (α-TUBB3; 1:1000). The DNA was stained with DAPI (1:15 000) containing RNase (200 ng/mL) over night at 4°C.
Cells were analyzed on a FC500 MCL Flow Cytometer (Beckman-Coulter, CA, USA). After collection of 15 000 events, results were analyzed with FlowJo software v7.6.5 (TreeStar, OR, USA).
Results
ANKK1 is Expressed in Both Fetal and Adult Human Brain
We studied the mRNA expression of ANKK1 in the prenatal and postnatal human prefrontal cortex (PFC). We found significantly higher levels of ANKK1 mRNA in fetal samples when compared with infant and adult samples (Fig. 1A) , suggesting a role of ANKK1 during prenatal brain development in humans. We further examined ANKK1 protein in PFC samples using 2 antibodies: α-STk, which recognizes identical human and mouse N-terminal peptides (Hoenicka et al. 2010) , and α-STk2, which was generated against a second mouse Ankk1 N-terminal peptide (Hoenicka et al. 2010 ) that cross-recognizes the human protein. Interestingly in adults, α-STk is specific for astrocytes in both humans and rodents (Hoenicka et al. 2010) , whereas α-STk2 is specific for neurons (see below in Fig. 3 ). We found that ANKK1 is expressed in the prenatal period, early and late postnatal periods and adulthood (Fig. 1B,C) . However, the observed biochemical pattern of the protein was complex. α-STk detected 3 bands (Fig. 1B) , the shortest of which may correspond to the ANKK1-kinase isoform (Hoenicka et al. 2010) , and 2 bands of approximately 70 and 92 kDa, which may correspond to either the predicted longest ANKK1 isoform (Hoenicka et al. 2010) or proteins modified by post-translational mechanisms. α-STk2 identified a approximately 70-kDa band and an approximately 84-kDa band (Fig. 1C) , which may also correspond to post-translationally modified ANKK1 isoforms. A faint approximately 56-kDa band was also detected by α-STk2 in samples from the third trimester of gestation.
To investigate the subcellular profile of human ANKK1 proteins, we performed Western blot studies of subcellular protein fractions of the human embryonic cell line HEK293T. Using both α-STk and α-STk2 antibodies, we observed different ANKK1 protein isoforms in the nucleus and other subcellular compartments (see Supplementary Fig. 1 ). Human samples therefore show an extremely complex ANKK1 expression pattern.
ANKK1 Expression Varies Along Neurodevelopment
To analyze the biology of ANKK1 during neurodevelopment, we studied Ankk1 expression in mice by determining mRNA and protein levels in whole-brain samples extracted in different embryonic days (E), early postnatal days (P) and adulthood. Ankk1 showed the highest mRNA levels throughout embryonic neurogenesis, followed by an oscillating pattern until the end of development at P10 ( Fig. 2A) . With regard to ANKK1 protein, in the mice brain α-STk detected specific patterns of ANKK1-kinase isoforms. The highest expression levels of murine Ankk1 coincided with gliogenesis ( Fig. 2B and Supplementary Fig. 2A ). Specifically, the approximately infants (n, 10; age 3.9 ± 4.9 years [Y]) and adults (n, 7; age 49.0 ± 25.7 years) revealed significant differences (one-way ANOVA, F= 5.3; P < 0.05; Student-Newman-Keuls post test, fetuses vs. infants *P < 0.01; fetuses vs. adults Relative mRNA values are shown for 3 independent assays; values were obtained and normalized as described in Materials 56-kDa band showed the highest expression level during late neurogenesis at E17.5 and until the end of gliogenesis in P10 (see Supplementary Fig. 2A ). These protein patterns varied depending on the subcellular (membrane or cytosolic) fraction and embryonic stage or animal age (see Supplementary Fig. 3A ) and might correspond to protein isoforms generated as a result of developmentrelated post-translational modifications of the ANKK1 kinase. α-STk2 also detected a complex but different pattern of ANKK1 isoforms including the ANKK1-kinase (∼56 kDa, ∼58 kDa) and the full-length ANKK1 (∼84 kDa, ∼92 kDa), (Fig. 2C and Supplementary  Fig 2B) . The approximately 56 kDa band, which was similar to that detected with α-STk, was expressed mainly during embryonic neurogenesis, whereas other isoforms were detectable during development and the early postnatal period (∼84 kDa), postnatal period (∼92 kDa) and adulthood (∼58 kDa) ( Fig. 2C and Supplementary  Fig 2B) . The highest expression level was observed in the approximately 56-kDa band at E13.5 and corresponds to a neurogenesis peak in the developing brain. During this period, expression of the approximately 56-kDa band was higher than expression of the approximately 84-kDa band (see Supplementary Fig. 2B ). In contrast during the gliogenic phase α-STk2 detected a reversed ANKK1 expression pattern. We observed higher levels for the ANKK1 isoform approximately 84-kDa band and low levels for the approximately 56-kDa band (see Supplementary Fig. 2B ). These isoforms were differentially expressed in the cytoplasmic cell fraction (∼84 kDa) and membrane cell fraction (∼56-kDa and ∼92-kDa bands) during development (see Supplementary  Fig. 3B ), again suggesting that the bands represent ANKK1 protein isoforms or post-translational modifications. Therefore, we found that α-STk and α-STk2 detected different ANKK1 isoforms with a phase-specific expression dynamics during neurodevelopment.
ANKK1 is Located in Progenitor Cells During Neurodevelopment
To gain further insights into the expression pattern of ANKK1 in neurodevelopment, we performed double immunolabeling with α-STk2 and α-RC2 (a RGC marker) or α-TUBB3 (as neuron-specific marker), in embryos at E14.5 and E17.5. In a previous study, we observed a complete overlap of α-STk2 and α-RC2 signals in frozen embryonic brain (Hoenicka et al. 2010) ; however, antigen unmasking of paraffin embedding embryonic brains additionally revealed α-STk2 signal in both RGCs and in some nuclei of cells distributed throughout the developing neural tube (see Supplementary Fig. 4A-D) . To identify the cell lineage associated with nuclear expression of ANKK1, we performed colabeling studies with α-TUBB3. We observed 4 different cell patterns regionally distributed throughout the developing central nervous system namely, ANKK1+/TUBB3−, ANKK1−/TUBB3−, ANKK1+/TUBB3+, and ANKK1−/TUBB3+ (Fig. 3 and Supplementary Figs 4 and 5). At E14.5, stage at which neurogenesis peaks, ANKK1 signal of variable intensity localized to the nucleus of differentiating TUBB3+ neuroblast from the spinal cord (late neurogenesis) to the telencephalon (mid neurogenesis) (Fig. 3) . We also observed ANKK1 signal in the nuclei of some progenitor cells localized to the ventricular zone (VZ) (Fig. 3E-H and Supplementary Fig. 4E-L) with the principal exception of the dorsal telencephalon, where the protein was absent at this stage. Later on, when neurogenesis is almost complete in the developing brain (E17.5), the ANKK1 signal was detected in both the nuclei of differentiating TUBB3+ neuroblast and most progenitors TUBB3− cells (Fig. 3I-L and Supplementary Figs 4M-T and 5). Specifically, in the striatum ANKK1 localizes to progenitors of the VZ, and also in the secondary proliferative population, which consists of nonepithelial progenitor cells located in a deeper subventricular zone (SVZ) (see Supplementary Fig. 5A-D) . In the hippocampal primordium, ANKK1 localizes to the nuclei of the VZ progenitor cells and migrating neuroblasts (see Supplementary Fig. 5E-H) . The cerebral neocortex was, however, quantitatively and qualitatively different at this stage. An ANKK1 signal of variable intensity was detected in the nuclei of cells from the progenitor cell pool in the VZ, which is composed of gliogenic and bipotent RGCs (75%) and basal progenitors (25%) (Pinto and Gotz 2007) (Fig. 3I-L) . The other cortical layers showed a scattered nuclear ANKK1 pattern (Fig. 3I-L and Supplementary Fig. 5I-L) .
Interestingly, we observed along the neural tube that ANKK1 was absent in the mitotic condensed chromosomes of RGCs and other neural progenitors (Fig. 3I-L and Supplementary Fig. 5A-H) . This observation together with the variation of ANKK1 signal intensity in the nuclei, especially in proliferative zones, suggests that this protein could be differentially regulated along the cell cycle.
ANKK1 is Located in Neural Stem Cells and Their Cell Progeny in the Adult Brain
We had previously detected ANKK1 in astrocyte cell bodies and processes in the adult brain using α-STk antibody (Hoenicka et al. 2010) . In the present study, we have further characterized the ANKK1 expression pattern in the adult brain using α-STk2. It is noteworthy that ANKK1 signal was broadly found in the nuclei of postmitotic neurons in structures all along the rostro-caudal axis of the adult mouse brain ( Fig. 3M-P) . In addition, we found ANKK1 expression in cells of the SVZ and the subgranular zone (SGZ) where the adult neurogenesis occurs (Lois and Alvarez-Buylla 1994; Eriksson et al. 1998) . In the SVZ, we identified an intense nuclear ANKK1 staining in type B (nuclei and processes) and type A (only nuclei) cells, which corresponded, respectively, to neural stem cells (NSCs) and migrating neuroblasts (Doetsch et al. 1997) (Fig. 4A-C) . Similarly to developing brain we observed ANKK1 exclusion from condensed chromosomes in the SVZ (Fig. 4F-I) .
The neurogenic niche in the hippocampal SGZ showed with α-STk2 signal in the nuclei of different cellular subtypes, as identified by doublecortin (DCX) and polysialylated form of the NCAM (PSA-NCAM) staining (Fig. 4L,M) , both of which are transiently expressed in the adult hippocampus from the proliferative progenitor cell phase to the postmitotic stage. Furthermore, analyses of cell-specific markers in monolayer cultures of adult hippocampal neural progenitor cells (AHNPCs) under proliferating conditions revealed colocalization of α-STk-or α-STk2-ANKK1 signals and the NSCs marker SOX2 (see Supplementary Fig. 6A-H) . These AHNPCs were able to differentiate into either astrocytes or neurons that express a brain pattern of ANKK1 isoforms as identified by α-STk (only astrocytes) or α-STk2 (only neurons) (Fig. 4N,O and Supplementary Fig. 6I-X) . 
ANKK1 Shows Differential Expression During the Cell Cycle
Given that ANKK1 expression varies in proliferative neural tissues (developing brain and adult SVZ/SGZ), we further studied whether this protein is connected to cell division cycle. We reversibly arrested human HeLa cells at the onset of S phase (G1/S arrest) by sequential thymidine/aphidicolin blocks and release in the presence of nocodazole to trap cells in mitosis (Fig. 5) . Western blots of total protein sampled collected at various times after release in the cell cycle showed qualitative and quantitative ANKK1 expression differences (Fig. 5A) . Further, the study of subcellular fractions showed that ANKK1 has a phase-specific protein profile in cytosol and nucleus (see Supplementary  Fig. 7A,B) . Along the cell cycle the 56-kDa band increased in the cytosol and dropped in the nuclear fraction. These changes were accompanied by CYCLIN B1 expression and JUN-B degradation (Fig. 5A) , both of which are well established mitotic markers (Farras et al. 2008) . ANKK1 expression was also studied by immunofluorescence of synchronized cells (see Supplementary  Fig. 7C ). We observed high intensity of ANKK1 in mitotic cells that was excluded from condensed chromosomes, whereas during interphase the protein was located in both the nucleus and the cytoplasm (see Supplementary Fig. 7C ).
To further study ANKK1 during the cell cycle, we performed flow cytometry studies of asynchronous HeLa, SH-SY5Y and HEK293T cells transfected with GFP-tagged ANKK1-kinase variants (Garrido et al. 2011) . We included the polymorphic ANKK1 Ala239 (in linkage disequilibrium with TaqIA A2 allele) and ANKK1
Thr239
(in linkage disequilibrium with TaqIA A1 allele) as well as ANKK1 Arg51 , which would lack the kinase activity (Garrido et al. 2011) . We found significant differences in all the phases of the ANOVA showed significant differences (G0/G1, F = 96.19, P < 0.0001; S, F = 65.57, P < 0.0001; G2/M, F = 66.72, P < 0.0001). Bars represent means of 5 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
cell cycle in HeLa (G0/G1, F = 7.381, P = 0.0016; S, F = 6.791, P = 0.0024; G2/M, F = 26.84, P < 0.0001), SH-SY5Y (G0/G1, F = 24.90, P < 0.0001; S, F = 8.683, P = 0.002; G2/M, F = 12.57, P = 0.0004) and HEK293T cells (G0/G1, F = 21.49, P < 0.0001; S, F = 14.18, P < 0.0001; G2/M, F = 23.94, P < 0.0001) (Fig. 5B,C and Supplementary Fig. 8 ). However, we observed differences among the cell lines. When compared with control cells (transfected with an empty expression plasmid), the G0/G1 phase showed a significant decrease in both SH-SY5Y (all ANKK1 variants: ANKK1
, P = 0.0275; ANKK1
Ala239
, P < 0.0001; ANKK1 Arg51 , P < 0.0004) and HeLa (only ANKK1 Thr239 , P = 0.0037) while an inverse effect was found in HEK293T cells (ANKK1 Ala239 , P = 0.0035 and ANKK1
Arg51
, P < 0.0001) (Fig. 5B,C and Supplementary  Fig. 8 ). The S phase showed an increase in SH-SY5Y (ANKK1 Ala239 , P = 0.0014 and ANKK1
, P = 0.0238) and a decrease in HEK293T (all ANKK1 variants: ANKK1 Thr239, P = 0.0117; ANKK1 Ala239, P < 0.0001;
ANKK1
Arg51
, P = 0.0015) (Fig. 5B,C and Supplementary Fig. 8 ). Cells in M phase were increased in both SH-SY5Y (all ANKK1 variants: ANKK1 Thr239 , P = 0.0924; ANKK1 Ala239 , P = 0.0020; ANKK1 Arg51 , P = 0.0005) and HEK293T (ANKK1 Thr239 , P < 0.0001; ANKK1 Ala239 , P= 0.0049) while in HeLa cells a decrease was found for ANKK1 Arg51 (P < 0.0001) (Fig. 5B ,C and Supplementary Fig. 8 ). Thus, ANKK1 overexpression cause cell line-specific changes in the cell-cycle phases especially in the G1 and M phase. We also studied the effect of the nonselective agonist at dopamine receptors apomorphine (APO) upon the cell cycle in SH-SY5Y and HEK293T cells transfected with GFP-tagged ANKK1-kinase variants. The APO treatment increased SH-SY5Y cells differences in all the phases of the cell cycle (G0/G1, F = 44.01, P < 0.0001; S, F = 9.051, P = 0.0012; G2/M, F= 35.51, P < 0.0001) (Fig. 5C) . Additionally, the comparison between treated and untreated SH-SY5Y cells showed significant differences only for the ANKK1 Ala239 variant in the G0/G1 (P = 0.001) and S (P < 0.0001) phases. These results suggest that ANKK1 allele and dopaminergic treatment would modulate ANKK1 effect upon the cycle in SH-SY5Y cells. In contrast, when we treated transfected HEK293T cells with APO, significant differences were only found in the G0/G1 phase (G0/G1, F = 6.292, P = 0.0056; S, F = 1.548, P = 0.2432; G2/M, F = 2.454, P = 0.1033) ( Supplementary Fig. 8 ). In HEK293T cells, APO treatment caused an antiproliferative effect as previously described for other cell lines (Scarselli et al. 1999) .
To study in vivo the role of ANKK1 in the cell cycle of the neural cells precursors, we performed flow cytometry of dissociated cells from E14.5 embryo forebrain (telencephalon and diencephalon). Forebrain cells were coimmunolabeled with α-STk2 and α-TUBB3 and the DNA stained with DAPI. Our results showed the same cell expression patterns for ANKK1 and TUBB3 (Fig. 5D ) that we had previously identified in E14.5 embryos by immunofluorescence experiments. The TUBB3+ cells were either nondividing neuroblast that exited the cell cycle (ANKK1−/TUBB3+; G0/G1: 97.36% ± 0.46, S: 2.57% ± 0.52, G2/M: 0) or slowly dividing cells that also express ANKK1 (ANKK1+/TUBB3+; G0/G1: 86.48% ± 1.05, S: 8.31% ± 1.02, G2/M: 3.10% ± 0.25) (Fig. 5E ). The other 2 groups of neural precursors, which were negative for TUBB3, would correspond to cells from the VZ and/or SVZ ( proliferative region). These progenitors were either ANKK1+ dividing cells with the shortest cell cycle length that could correspond to selfrenewal cells (ANKK1+/TUBB3− ; G0/G1: 68.22% ± 1.78, S: 26.23% ± 1.80, G2/M: 5.55% ± 0.57) or ANKK1− cells with a long G0/G1 phase (ANKK1−/TUBB3− ; G0/G1: 88.98% ± 1.03, S: 11.02% ± 1.03, G2/M: 0). The comparison of cell-cycle phases among the 4 cells subgroups showed significant differences (Fig. 5E ). Post hoc analyses also showed significant differences with the exception of G0/G1 and S phases between ANKK1+/TUBB3+ versus ANKK1−/TUBB3− subgroups (G0/G1: 86.48 vs. 88.98%, P = 0.643; S: 8.31 vs. 11.02%, P = 0.962) (Fig. 5E ). In addition, we observed a direct correlation between the occurrence of M phase and the expression of ANKK1 (Fig. 5E ). Taken together these results support the notion that ANKK1 could be involved in the cell cycle regulation of neural progenitors and neuroblasts.
Discussion
Despite the huge number of studies regarding the role of the ANKK1 TaqIA polymorphism in addictions and other behaviors (Noble 2003; Ponce et al. 2009 ) the part played by ANKK1 gene and its protein in these disorders it is not known yet. Previous data on ANKK1 biology have demonstrated its expression in embryonic and adult brain (Hoenicka et al. 2010) . Further, in human culture cells, recombinant ANKK1 localizes in nucleus and cytoplasm and its polymorphic variants show expression differences at basal level and when stimulated with apomorphine (Garrido et al. 2011) . In this study we are presenting, for the first time, a fundamental biological support for the association between TaqIA and psychiatric phenotypes, and their possible relationship with brain structure. Our findings can be summarized as follows: first, regulation of ANKK1 mRNA and protein isoforms is extremely complex during neurodevelopment; second, in mouse adult brain ANKK1 is located in astrocytes, the nuclei of postmitotic neurons and neural precursors; third, ANKK1 has an impact upon G1 and M phase of the cell cycle that it is also affected by ANKK1 polymorphisms and apomorphine treatment; and fourth, during embryonic neurogenesis ANKK1 is expressed in both slow-dividing neuroblasts (TUBB3+) and rapidly-dividing precursors (TUBB3−) groups, which are mitotic cells.
Our results are in line with locus-related developmental impact of chromosome 11q22-23 cluster where ANKK1 maps, upon vulnerability to addiction. This cluster shows a conserved synteny and neighborhood of the NCAM1, TTC12, ANKK1, and DRD2 genes (Mota et al. 2012) . Indeed, the TaqIA polymorphism located in the exon 8 of ANKK1 affects the expression of the neighboring gene DRD2 (Zhang et al. 2007 ). Moreover, ANKK1 belongs to the RIP family, which participates in differentiation processes in a broad variety of cell types and tissues (Meylan and Tschopp 2005) . For instance, RIP2 plays a role in myogenic differentiation (Munz et al. 2002) ; RIP4, the most similar in the overall structural organization to ANKK1 protein, is a regulator of both epidermal morphogenesis during development and cutaneous wound repair (Adams and Munz 2010) , and RIP7 is involved in neuronal differentiation (Bahnassawy et al. 2013 ).
During neurodevelopment the major function of stem cells and progenitors is cell production and differentiation. Thus, the location of ANKK1 in different neural progenitor cells and its expression during the M phase of the cell cycle is remarkable.
A number of mitosis biology aspects have been implicated in neurogenesis (Gotz and Huttner 2005) . RGCs divide asymmetrically at the apical surface, producing neurons in both humans (Mo et al. 2007; Franco et al. 2012 ) and rodents (Malatesta et al. 2003; Gotz and Barde 2005; Pinto and Gotz 2007) ; or producing progenitor cells that undergo symmetric neurogenic divisions (Haubensak et al. 2004; Noctor et al. 2004 ). Very recently, it has been reported that prolonged mitosis directly alters balanced divisions of RGCs, generating more neurons and apoptotic progeny (Pilaz et al. 2016) . In this study, we have demonstrated that ANKK1 expression increased during mitosis in the cytosol of synchronized cells, lengthened the M phase after its overexpression in SH-SY5Y neuroblastoma cells and localized exclusively in the dividing E14.5 mice forebrain cells subgroups. These results suggest a role of ANKK1 during mitosis in both neurogenesis and self-renewal neural progenitors. Furthermore, the forebrain cells subgroups ANKK1+/TUBB3+ and ANKK1−/TUBB3− that showed identical length of their G1 and S phase, differed in the presence or absence of mitosis, respectively. Since lengthening of G1 phase has been associated with neuron production (Dehay and Kennedy 2007) , it is tempting therefore to propose a relationship between G1 phase lengthening before neurogenic mitosis and expression of TUBB3 and ANKK1 in early neuroblast. Additionally, ANKK1 qualitative and quantitative expression changes during development detected by α-STk (adult astrocytes) and α-STk2 (adult neurons) followed a temporary pattern. These observations may suggest that ANKK1 has a cell-specific isoforms pattern that could be temporary established from progenitors and it is kept in differentiated cells. Using α-STk2 we observed high expression of 56 kDa ANKK1 in embryonic mouse brain at E13.5 ( proliferative stage) together with low levels of 84 kDa. A reversed expression pattern was found during post-natal development that is a stage of neurons maturation and synaptogenesis (Gotz and Huttner 2005) . In contrast, α-STk detected strong expression of 56-kDa ANKK1 during gliogenesis from E15.5 until P5. Therefore, ANKK1 could have a crucial role in different stages during brain development related to proliferative activity, differentiation, and/or maturation of neural progenitor cells.
In clinical terms, our results provide molecular evidence for the previous association between hereditary human brain structure differences and increased risk for developing drug addiction (Ersche et al. 2012 ). ANKK1-kinase polymorphic alleles would impact prenatal pathways during development that could tag brain structure in such a way as to render an individual vulnerable to TaqIA-mediated conditions. Additionally, expression of ANKK1 can also undergo significant changes during drug-induced effects and neuroadaptations affecting brain cells and neurogenic niches that could also be associated with ANKK1 polymorphic alleles. In animal models, recent findings have shown after drug exposure that a below-normal level of neurogenesis is a common abnormality, whereas increased neurogenesis may be protective (Mandyam and Koob 2012) . Our findings may also apply to other reward-related disorders linked to TaqIA. For instance, a TaqIAassociated blunted striatal response to food (Stice et al. 2008) have been linked to obesity. Finally, antisocial disorders that are frequently comorbid with addictions (Langas et al. 2012) have also been associated with TaqIA (Ponce et al. 2003 (Ponce et al. , 2008 (Ponce et al. , 2009 , structural brain differences (Gregory et al. 2012) , and juvenile neurogenesis (Wei et al. 2011 ).
In conclusion, we provide the first evidence of the function of ANKK1 in the developing and adult brain. Hence, the TaqIA-associated phenotypes can no longer be explained only by functional variations in D2R, as our findings support a role for ANKK1 in the cell cycle during embryonic neurogenesis that could be differentially regulated by TaqIA polymorphism alleles and it is affected by dopaminergic treatments. We propose that both inherited differences in brain structure and environment-induced changes involving ANKK1 polymorphic variants facilitate expression of addictions and other dopaminergic traits associated with the TaqIA SNP.
